Program
TQB2825
A development code. Also written as “TQB2825 injection +R-CHOP regimen”, “TQB2825 injection + GemOx” and “TQB2825 Injection”.
In Sino Biopharmaceutical's pipeline, CD20/CD3双抗
. Its studies are mostly in Lymphoma, Large B-Cell, Diffuse · Lymphoma, Follicular · Hematologic Neoplasms, led by Sino Biopharmaceutical.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Sino Biopharmaceutical | 54 open or running | phase 3since Sep 17, 2025 | Jun 17, 2022 | Oct 2028phase 3 · NCT07187960 |
- Named in Sino Biopharmaceutical’s own pipeline as
TQB2825
, phase 3, as of Nov 16, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Jun 17, 2022First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05489276 · 180 enrolled · China
- Feb 12, 20252 phase 2 studies in Lymphoma, Large B-Cell, DiffuseNCT06829771, NCT06854445
- Jul 31, 2025Phase 1 study in CD20-positive Hematological MalignanciesNCT07110194 · 75 planned · China
- Sep 17, 2025Phase 3 study in Lymphoma, FollicularNCT07187960 · 228 planned · China
Ahead
- Oct 2028Primary completion: phase 3 study in Lymphoma, FollicularNCT07187960
TargetBeta
“CD20/CD3双抗”the company's pipeline, read by Claude · source
Other programs on the same two targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| mosunetuzumabrule | Hoffmann-La Roche | phase 3 | 14 |
| glofitamabrule | Hoffmann-La Roche | phase 3 | 13 |
| epcoritamabrule | Genmab | phase 3 | 13 |
| odronextamabrule | Regeneron Pharmaceuticals | phase 3 | 8 |
| Anti-CD20/Anti-CD3/Anti-CD8 Trispecific Antibody AZD5492 | AstraZeneca | phase 2 | 2 |
| GSK5926371 | GlaxoSmithKline | phase 2 | 2 |
| REGN9220rule | Regeneron Pharmaceuticals | phase 2 | 1 |
| Anti-CD79b/CD20/CD3 Trispecific Antibody JNJ-80948543rule | Johnson & Johnson | phase 1 | 3 |
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07187960Lymphoma, Follicular · China | 3 | Not yet recruiting | Oct 2028 | 228 |
| NCT07110194CD20-positive Hematological Malignancies · China | 1 | Not yet recruiting | Mar 2026 | 75 |
| NCT06854445Lymphoma, Large B-Cell, Diffuse · China | 2 | Recruiting | Oct 2025 | 55 |
| NCT06829771Lymphoma, Large B-Cell, Diffuse · China | 2 | Recruiting | May 2026 | 90 |
| NCT05489276Hematologic Neoplasms · China | 1 | UNKNOWN | Oct 2023 | 180 |
How it is read
Names in the registry
- “TQB2825 injection +R-CHOP regimen”, 1 entry
- “TQB2825 injection + GemOx”, 1 entry
- “TQB2825 Injection”, 1 entry
- “TQB2825 Injection (Subcutaneous Injection)”, 1 entry
- “TQB2825 Injection + Gemcitabine Hydrochloride for Injection + Oxaliplatin for Injection”, 1 entry
Codes read as this program: TQB2825.
Conditions, from the studies’ own filings
- Lymphoma, Large B-Cell, Diffuse, 2 studies
- Lymphoma, Follicular, 1 study
- Hematologic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.